Hims & Hers Health, Inc. (NYSE: HIMS): Hims & Hers, Inc. (“Hims & Hers” or the “Company”) and certain of the Company’s senior executives have been sued for violations of the federal securities laws. Two cases are pending in the U.S. District Court for the Northern District of California: Sookdeo v. Hims & Hers Health, Inc., et al., No. 25-cv-05315 and Yaghsizian v. Hims & Hers Health, Inc., et al., No. 25-cv-05321. The complaints assert claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Hims & Hers securities. 

If you incurred losses on your investments in Hims & Hers, you are encouraged to submit your information.

Why was Hims & Hers Sued for Securities Fraud?
 
Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products.
 
On April 29, 2025, Hims & Hers and Novo Nordisk announced a “long-term collaboration” starting with the immediate sale of Novo Nordisk’s popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide.   
 
As alleged, Hims and Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations.  
 
In truth, Novo Nordisk did not approve of Hims & Hers’s sale of compounded semaglutide alongside Wegovy, and Hims & Hers engaged in deceptive marketing and the illegal sale of “knockoff versions” of Wegovy.

The Stock Declines as the Truth is Revealed
 
On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, “based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk” and alleged that Hims & Hers “failed to adhere to the law which prohibits mass sales of compounded drugs.” On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025.

What are my Rights?

If you purchased or otherwise acquired Hims & Hers securities, you may ask the Court no later than August 25, 2025, which is the first business day after 60 days from the date of publication of the notice of pendency, to appoint you as Lead Plaintiff through counsel of your choice. To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.

If you incurred losses on your investments in Hims & Hers, you are encouraged to submit your information to speak with an attorney about your rights.  

You can also contact:
Ross Shikowitz
ross@bfalaw.com
212-789-3619

All representation is on a contingency fee basis. Shareholders are not responsible for any court costs or expenses of litigation. The Firm will seek court approval for any potential fees and expenses.

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
 
Attorney advertising. Past results do not guarantee future outcomes.